UNSPSC 51283609: Rifamycin o

This classification denotes an antitubercular agent with the molecular formula C39H47NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z67LEM9P1W, chemically known as 4-o-(carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxorifamycin .gamma.-lactone, but more generally known as rifamycin o, which bears US NIH Compound Identifier 5280468. European Medicines Agency schedules rifamycin o or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG.

Most nations, for tariff purposes, schedule rifamycin o under HS 29419000. SMILES: CC1C(C2C3C4C1O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/C=C(\C(=O)NC(=CC35OCC(=O)O5)C2=O)/C)C)O)C)O)C)OC(=O)C)C)OC)C)O.

UNSPSC 51283609 Rifamycin o is a Commodity-level code that in recent state and local procurement appears misaligned with its nominal pharmaceutical scope. The four most recent opportunities tagged to this code cover naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), medical and first aid supplies for fire rescue (City of Tampa), and generic multi-source pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations reference rifamycin, an antibiotic typically used in tuberculosis treatment, suggesting the code does not match the work actually being bought or the code assignment is incorrect in the source data. The issuing bodies include county health departments, state health agencies, municipal fire departments, and state cooperative purchasing alliances. Geographic activity spans Florida, Texas, Minnesota, and Oregon through cooperative arrangements.

The source shows no coherent recent procurement activity under this code's nominal pharmaceutical scope. The four opportunities represent distinct commodity categories—controlled-substance management, pharmacy benefit program design, emergency medical supplies, and generic drug supply chains—none of which align with rifamycin procurement. Without recent opportunities that substantively match the code's stated drug classification, this code shows little decision-relevant activity for vendors focused on antibiotic supply or manufacturing. The mismatch between the code's name and the actual solicitations posted against it suggests either data-quality issues in the source or the code's disuse in active state and local procurement.